Copyright
©The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Pathophysiol. Aug 15, 2015; 6(3): 79-85
Published online Aug 15, 2015. doi: 10.4291/wjgp.v6.i3.79
Published online Aug 15, 2015. doi: 10.4291/wjgp.v6.i3.79
Human microbiome: From the bathroom to the bedside
Stephen Malnick, Department of Internal Medicine C, Kaplan Medical Center, Affiliated to the Hebrew University, Rehovot 76100, Israel
Ehud Melzer, Institute of Gastroenterology and Liver Disease, Kaplan Medical Center, Affiliated to the Hebrew University, Rehovot 76100, Israel
Author contributions: Both authors contributed to this manuscript.
Conflict-of-interest statement: No potential conflicts of interest relevant to this article were reported.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Stephen Malnick, MA (Oxon), MSc, MBBS (Lond), Director, Department of Internal Medicine C, Kaplan Medical Center, Affiliated to the Hebrew University, Jerusalem, Rehovot 76100, Israel. stephen@malnick.net
Telephone: +972-8-9441371 Fax: +972-8-9441852
Received: February 3, 2015
Peer-review started: February 4, 2015
First decision: March 20, 2015
Revised: April 17, 2015
Accepted: April 28, 2015
Article in press: April 30, 2015
Published online: August 15, 2015
Processing time: 195 Days and 4.2 Hours
Peer-review started: February 4, 2015
First decision: March 20, 2015
Revised: April 17, 2015
Accepted: April 28, 2015
Article in press: April 30, 2015
Published online: August 15, 2015
Processing time: 195 Days and 4.2 Hours
Core Tip
Core tip: Fecal microbial transplantation is approved for the treatment of recurrent Clostridium difficile infection by either nasojejunal administration or colonoscopy. In addition there is some evidence for its use in both irritable bowel syndrome and inflammatory bowel disease. There are, however, reports of side effects including weight gain, diverticulitis and development of autoimmune disease. Treatment for non-approved conditions should be performed in the framework of clinical research trials in order to better define the indications.